Abatacept Articles
UK's NICE draft guidance recommends Bristol-Myers Orencia for RA
6 December 2012
More news at EULAR from Novartis, J&S and B-MS
7 June 2012
Bristol-Myers gets more rights to Ono antibody in exchange for Japan co-rights to Orencia
22 September 2011
Bristol-Myers Squibb’s Orencia gets expanded indication in Europe and Reyataz cleared for pediatric use
8 July 2010
Bristol-Myers Squibb forecasts large jump in 2010 profit to range of $1.94 to $2.04 per share
29 January 2010
European Commission approves Bristol-Myers Squibb’s Orencia for combination use in pJIA
26 January 2010
Judgement in favor of UK NICE on judicial review of B-MS Orencia for rheumatoid arthritis guidance
9 November 2009
Bristol-Myers sees 64% leap in 3rd quarter 2009 ongoing earnings
23 October 2009
B-MS' 1st qtr hit by tax and legal costs
29 April 2009
B-MS to use XDx tests to develop Orencia
19 January 2009
B-MS' Orencia almost doubles RA remission
3 November 2008
Bristol-Myers Squibb's 3rd-qtr 2008 profit triples due to big gain from $4.1B sales of ConvaTec
3 November 2008
B-MS presents JIA drug QOL data at ACR
3 November 2008
B-MS' profit accelerates on good exchange rate
4 August 2008
NICE rejects second-line use of TNF-alpha drugs
28 July 2008
Orencia inhibits joint damage through three years
23 June 2008
"Condemned to a life of misery" by UK's NICE
5 May 2008
FDA approves B-MS' Orencia for JIA
14 April 2008
Strong long-term efficacy and safety data for Orencia
19 November 2007
US FDA accepts sBLA for B-MS' Orencia
13 August 2007
EC clears B-MS' Orencia for RA
4 June 2007
B-MS' Orencia gets stronger US labeling
7 May 2007
B-MS completes land purchase for new production site
26 February 2007
RA biological competitors spent $195M on promotion
8 January 2007
B-MS reports two-year Orencia data in RA
20 November 2006
B-MS discusses two-year Orencia trial data
3 July 2006
B-MS's Orencia performs well in trials
15 May 2006
B-MS to invest $200M in Puerto Rico plant expansion
3 April 2006
Avidex sees positive data from RhuDex trials
20 March 2006
B-MS to build new $660M US biologics plant
13 March 2006
4th-qtr 2005 sales drop 1% for B-MS, as patents lost
30 January 2006
Repligen claims patent suit on B-MS' Orencia
16 January 2006
B-MS completes Orencia sBLA
9 January 2006
B-MS's arthritis drug Orencia gets FDA go ahead
9 January 2006
B-MS announces cost-cutting plans
19 December 2005
US FDA advisers urge appro of B-MS' Orencia
12 September 2005
Celltrion to make biologicals for B-MS
27 June 2005
B-MS' Abatacept inhibits RA damage
20 June 2005
UPDATE: B-MS submits muraglitazar in the USA
10 January 2005
B-MS submits muraglitazar in the USA
10 January 2005
B-MS reacts to WSJ
12 July 2004
Showing 1-66 of 66 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
